Actively Recruiting
Photoacoustic/Ultrasound Imaging of Brown Adipose Tissue Activity
Led by Peking Union Medical College Hospital · Updated on 2026-01-08
100
Participants Needed
1
Research Sites
136 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this study is to develop a novel, non-invasive, real-time photoacoustic imaging (PAI) technology for quantifying brown adipose tissue (BAT) and to investigate the differences in BAT morphology and metabolic function between healthy individuals and patients with metabolic syndrome. The main questions it aims to answer are: 1. Can PAI technology quantify BAT metabolic function and establish standardized PAI parameters for BAT assessment? 2. Can PAI parameters distinguish the BAT characteristics of healthy volunteers from patients with metabolic syndrome? Both healthy adults and patients diagnosed with metabolic syndrome will be recruited. Participants will undergo PAI scans of BAT region under normal conditions and after cold exposure to assess BAT activation. The ultimate goal is to validate this radiation-free PAI method as a convenient and effective tool for evaluating BAT metabolism, potentially aiding in early diagnosis and treatment monitoring of metabolic syndrome.
CONDITIONS
Official Title
Photoacoustic/Ultrasound Imaging of Brown Adipose Tissue Activity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy individuals over 18 years of age with BMI less than 30
- No history of metabolic diseases, rheumatic immune diseases, or cardiovascular and cerebrovascular diseases
- Not currently using any sympathomimetic or sympatholytic drugs
- Non-smoker and does not consume excessive alcohol
- Patients aged 18 to 60 years diagnosed with metabolic syndrome meeting three or more specific criteria including waist circumference, blood glucose, blood pressure, triglycerides, or HDL cholesterol
- Patients diagnosed with Polycystic Ovary Syndrome (PCOS) meeting two or more specific diagnostic criteria and excluding other endocrine diseases
You will not qualify if you...
- Weight change greater than 5% within 3 months prior to enrollment
- BMI of 30 or higher
- Diagnosis of metabolic disease, rheumatic immune disease, cardiovascular or cerebrovascular disease, or malignant tumor
- Use of sympathomimetic or sympatholytic drugs within 3 months prior to enrollment
- Smoker or consumes excessive alcohol
- Diagnosis of Raynaud's disease or intolerance/allergy to cold stimulation
- Currently pregnant, lactating, or menstruating
- Contraindications to radionuclide tracer Fluorodeoxyglucose (18F-FDG) injection or unsuitable for PET-CT examination
- Diagnosis of Type 1 diabetes or other specific diabetes types
- Presence of acute or severe chronic diabetic complications
- History of acute or chronic pancreatitis or pancreatic tumors
- Recent serious heart conditions including heart failure, unstable angina, or myocardial infarction within 12 months
- Severe hepatic or renal dysfunction
- Comorbid malignant tumors or other severe chronic diseases
- Received glucose-lowering therapy within 3 months prior or extensive treatment in past 2 years
- Diagnosis of rheumatic immune diseases
- Diagnosis of Raynaud's disease or intolerance/allergy to cold stimulation
- Currently pregnant, lactating, or menstruating
- Contraindications to radionuclide tracer Fluorodeoxyglucose (18F-FDG) injection or unsuitable for PET-CT examination
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, China
Actively Recruiting
Research Team
M
Meng Yang, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here